Literature DB >> 15261304

Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins.

Rocio García-Becerra1, Austin J Cooney, Elizabeth Borja-Cacho, Ana E Lemus, Gregorio Pérez-Palacios, Fernando Larrea.   

Abstract

Synthetic 19-nortestosterone-derived progestins show affinity for the androgen receptor (AR) and retain varying degrees of androgenic activity. In this study, AR- and progesterone receptor (PR)-dependent transcriptional activation induced by norethisterone (NET), levonorgestrel (LNG) and gestodene (GSD), and their 5alpha-reduced derivatives, including limited trypsin digestion of AR in the presence of natural and synthetic progestins were investigated. The results confirmed the progestogenic activity of the three 19-nortestosterone derivatives, which decreases after reduction of the 4-ene-double bound. These compounds were able to activate AR-dependent reporter gene expression, LNG and GSD being the stronger activators. 5alpha-Reduction of LNG and GSD did not change their androgenic transcriptional activity; however, the activation of AR by 5alpha-NET was four-fold higher than NET. The highest selectivity transcriptional index, as a measure of progestogenicity versus androgenicity, was obtained for NET. The 5alpha-reduced derivatives had values significantly lower than those of their parent compounds. Non-reduced and 5alpha-reduced 19-nortestosterone progestins induced virtually identical proteolysis fragmentation patterns of the AR to those observed with DHT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261304     DOI: 10.1016/j.jsbmb.2004.02.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  3 in total

Review 1.  Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Authors:  Frank Z Stanczyk; Janet P Hapgood; Sharon Winer; Daniel R Mishell
Journal:  Endocr Rev       Date:  2012-12-13       Impact factor: 19.871

Review 2.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

3.  The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive-A randomized controlled trial.

Authors:  Marcus-Hillert Schultze-Mosgau; Barbara Schütt; Corinna Draeger; Manuela Casjens; Stephanie Loewen; Torsten Zimmermann; Beate Rohde
Journal:  Br J Clin Pharmacol       Date:  2020-07-24       Impact factor: 3.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.